SG11201901937WA - Pyridine compound - Google Patents
Pyridine compoundInfo
- Publication number
- SG11201901937WA SG11201901937WA SG11201901937WA SG11201901937WA SG11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA SG 11201901937W A SG11201901937W A SG 11201901937WA
- Authority
- SG
- Singapore
- Prior art keywords
- chuo
- tokyo
- limited
- international
- honcho
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016191725A JP2018052878A (ja) | 2016-09-29 | 2016-09-29 | ピリジン化合物 |
| PCT/GB2017/052913 WO2018060714A1 (en) | 2016-09-29 | 2017-09-28 | Pyridine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901937WA true SG11201901937WA (en) | 2019-04-29 |
Family
ID=60020249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901937WA SG11201901937WA (en) | 2016-09-29 | 2017-09-28 | Pyridine compound |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10851092B2 (ro) |
| EP (2) | EP3519398B1 (ro) |
| JP (2) | JP2018052878A (ro) |
| KR (1) | KR102520543B1 (ro) |
| CN (2) | CN113788824A (ro) |
| AU (2) | AU2017335242C1 (ro) |
| BR (1) | BR112019006047A2 (ro) |
| CA (1) | CA3035860A1 (ro) |
| CL (1) | CL2019000844A1 (ro) |
| CO (1) | CO2019004034A2 (ro) |
| CY (1) | CY1123988T1 (ro) |
| DK (1) | DK3519398T3 (ro) |
| EA (1) | EA037103B1 (ro) |
| EC (1) | ECSP19030134A (ro) |
| ES (1) | ES2868748T3 (ro) |
| HR (1) | HRP20210447T1 (ro) |
| HU (1) | HUE054824T2 (ro) |
| IL (1) | IL265630B (ro) |
| LT (1) | LT3519398T (ro) |
| MA (2) | MA46337B1 (ro) |
| MD (1) | MD3519398T2 (ro) |
| MX (1) | MX2019003747A (ro) |
| PE (1) | PE20190805A1 (ro) |
| PH (1) | PH12019500480A1 (ro) |
| PL (1) | PL3519398T3 (ro) |
| PT (1) | PT3519398T (ro) |
| RS (1) | RS61640B1 (ro) |
| SG (1) | SG11201901937WA (ro) |
| SI (1) | SI3519398T1 (ro) |
| UA (1) | UA123964C2 (ro) |
| WO (1) | WO2018060714A1 (ro) |
| ZA (1) | ZA201902232B (ro) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194262A (en) | 2015-11-02 | 2022-11-25 | Blueprint Medicines Corp | Inhibitors of ret |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| JP7422084B2 (ja) | 2018-04-03 | 2024-01-25 | ブループリント メディシンズ コーポレイション | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CN115087463A (zh) * | 2019-11-18 | 2022-09-20 | 中外制药株式会社 | 并用药物 |
| CN113121524B (zh) | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021164742A1 (zh) * | 2020-02-20 | 2021-08-26 | 广州白云山医药集团股份有限公司白云山制药总厂 | 喹啉类化合物 |
| WO2021164741A1 (zh) * | 2020-02-20 | 2021-08-26 | 南京明德新药研发有限公司 | 苯基双酰胺类化合物 |
| WO2022238706A1 (en) | 2021-05-14 | 2022-11-17 | Bp Asset Viii, Inc. | Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer |
| AU2022463015A1 (en) | 2021-10-22 | 2024-05-09 | Tract Pharmaceuticals, Inc. | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| CN115090331B (zh) * | 2022-07-21 | 2023-05-16 | 扬州大学 | 超分子手性催化剂、其制备方法及其催化d-a反应的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
| US20090076075A1 (en) | 2006-03-02 | 2009-03-19 | Frederic Henri Jung | Quinoline derivatives |
| JP2009528335A (ja) | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| WO2007113565A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| WO2007113548A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| BRPI1008308B8 (pt) * | 2009-02-27 | 2021-05-25 | Teijin Pharma Ltd | processo para produzir um composto |
| MX2012001974A (es) | 2009-08-19 | 2012-04-11 | Ambit Biosciences Corp | Compuestos de biarilo y metodos de uso de los mismos. |
| DK2470173T3 (en) | 2009-08-25 | 2016-06-06 | Abraxis Bioscience Llc | Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors |
| CN102946881A (zh) | 2010-04-23 | 2013-02-27 | 奇尼塔公司 | 抗病毒化合物 |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| PT2970191T (pt) | 2013-03-15 | 2017-03-23 | Glaxosmithkline Ip Dev Ltd | Derivados de piridina como inibidores da quinase rearranjada durante transfecção(ret) |
| KR20160055170A (ko) | 2013-08-30 | 2016-05-17 | 암비트 바이오사이언시즈 코포레이션 | 바이아릴 아세트아미드 화합물 및 이의 사용 방법 |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| US9783522B2 (en) * | 2014-04-24 | 2017-10-10 | Mitsubishi Tanabe Pharma Corporation | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof |
| JP6538154B2 (ja) * | 2014-09-10 | 2019-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｅｔ（ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ）キナーゼ阻害剤としてのピリジン誘導体 |
| JP6538153B2 (ja) * | 2014-09-10 | 2019-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物 |
| JP6899323B2 (ja) | 2014-10-14 | 2021-07-07 | ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー | 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用 |
| CN104844589B (zh) | 2014-12-26 | 2018-04-20 | 中国科学院合肥物质科学研究院 | 一种pi3k激酶抑制剂 |
| WO2016127074A1 (en) * | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| SI3322706T1 (sl) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
-
2016
- 2016-09-29 JP JP2016191725A patent/JP2018052878A/ja active Pending
-
2017
- 2017-09-28 UA UAA201904549A patent/UA123964C2/uk unknown
- 2017-09-28 EP EP17780169.3A patent/EP3519398B1/en active Active
- 2017-09-28 MD MDE20190863T patent/MD3519398T2/ro unknown
- 2017-09-28 DK DK17780169.3T patent/DK3519398T3/da active
- 2017-09-28 EP EP21151210.8A patent/EP3828178A1/en not_active Withdrawn
- 2017-09-28 ES ES17780169T patent/ES2868748T3/es active Active
- 2017-09-28 MA MA46337A patent/MA46337B1/fr unknown
- 2017-09-28 CN CN202111188408.2A patent/CN113788824A/zh active Pending
- 2017-09-28 HU HUE17780169A patent/HUE054824T2/hu unknown
- 2017-09-28 SI SI201730683T patent/SI3519398T1/sl unknown
- 2017-09-28 AU AU2017335242A patent/AU2017335242C1/en active Active
- 2017-09-28 CN CN201780074582.XA patent/CN110036007B/zh active Active
- 2017-09-28 SG SG11201901937WA patent/SG11201901937WA/en unknown
- 2017-09-28 KR KR1020197012323A patent/KR102520543B1/ko active IP Right Grant
- 2017-09-28 CA CA3035860A patent/CA3035860A1/en active Pending
- 2017-09-28 US US16/337,896 patent/US10851092B2/en active Active
- 2017-09-28 MX MX2019003747A patent/MX2019003747A/es unknown
- 2017-09-28 JP JP2019516670A patent/JP7098609B2/ja active Active
- 2017-09-28 MA MA054910A patent/MA54910A/fr unknown
- 2017-09-28 PL PL17780169T patent/PL3519398T3/pl unknown
- 2017-09-28 EA EA201990833A patent/EA037103B1/ru unknown
- 2017-09-28 PT PT177801693T patent/PT3519398T/pt unknown
- 2017-09-28 BR BR112019006047A patent/BR112019006047A2/pt not_active Application Discontinuation
- 2017-09-28 PE PE2019000730A patent/PE20190805A1/es unknown
- 2017-09-28 LT LTEP17780169.3T patent/LT3519398T/lt unknown
- 2017-09-28 RS RS20210332A patent/RS61640B1/sr unknown
- 2017-09-28 WO PCT/GB2017/052913 patent/WO2018060714A1/en unknown
-
2019
- 2019-03-05 PH PH12019500480A patent/PH12019500480A1/en unknown
- 2019-03-26 IL IL265630A patent/IL265630B/en unknown
- 2019-03-28 CL CL2019000844A patent/CL2019000844A1/es unknown
- 2019-04-09 ZA ZA2019/02232A patent/ZA201902232B/en unknown
- 2019-04-23 CO CONC2019/0004034A patent/CO2019004034A2/es unknown
- 2019-04-29 EC ECSENADI201930134A patent/ECSP19030134A/es unknown
-
2020
- 2020-11-24 US US17/103,515 patent/US20210163464A1/en not_active Abandoned
-
2021
- 2021-03-17 CY CY20211100228T patent/CY1123988T1/el unknown
- 2021-03-17 HR HRP20210447TT patent/HRP20210447T1/hr unknown
- 2021-11-03 AU AU2021261899A patent/AU2021261899A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901937WA (en) | Pyridine compound | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201403402VA (en) | Compounds | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201901389XA (en) | Combination therapy with glutaminase inhibitors |